

Cost-effectiveness Thresholds for Decision Making about Health Care Technologies: Conceptual and Empirical Underpinnings

Chair

Mark Sculpher, PhD

Professor of Health Economics

Centre for Health Economics

University of York, UK

iHEA, Toronto, July 2011

Background

- Widespread use of economic evaluation to support decisions regarding new medical technologies
- Some form of cost-effectiveness analysis predominates
 - Measure of (health) effects in natural units
- Costs and effects ultimately have to be valued in commensurate units for decision making

Decision rules

- Standard ICER decision rule:

$$\Delta C / \Delta E < \lambda$$

Where λ is the threshold


- Net monetary benefit:

$$(\Delta E \times \lambda) - \Delta C > 0$$

- Net health benefit:

$$\Delta E - (\Delta C / \lambda) > 0$$

The region of cost-effectiveness



Alternative sources of the threshold

Implicit and variable

- Lacks transparency
- Doing more good than harm?
- Ignores economic meaning

Empirical estimation

- Implied by budget constraint
Local detail vs. national average
- Willingness to pay
Preference-based vs. policy defined
- Previous decisions
Empirical estimate vs. rule of thumb

Some considerations

- Which type of health care system?
 - Budget constrained
 - Freely funded
 - Mixed
- Should threshold vary by clinical area?
- What methods and datasets exist for estimation?
- What level of precision is need in the estimate?
- How do we deal with the inevitable uncertainty?
- Can different concepts of the threshold co-exist?
- How often should the threshold be re-estimated?
- Should the threshold only reflect only unweighted health?

Our speakers

Karl Claxton

Professor of Economics, Centre for Health Economics and
Department of Economics, University of York, UK

Adrian Towse

Director, Office of Health Economics, London, UK

Andreas Gerber

Head of Health Economics, IQWiG, and University of
Cologne, Cologne, Germany